Samaritan fusion inhibitor progress
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Samaritan expects to begin a Phase II/III monotherapy trial of its HIV fusion/entry inhibitor SP-01A in the second quarter, the firm says March 1. The trial will look at HIV patients experiencing resistance to antiretroviral therapy. Samaritan is touting SP-01A's oral capsule formulation as an advantage over the only marketed fusion inhibitor, Roche/Trimeris' subcutaneous Fuzeon (enfuvirtide). Other firms with fusion inhibitors in development include Progenics and Biogen Idec...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.